Revenue Showdown: Walgreens Boots Alliance, Inc. vs TG Therapeutics, Inc.

Revenue Showdown: Walgreens Boots Alliance vs. TG Therapeutics

In the ever-evolving landscape of the pharmaceutical and healthcare industry, revenue trends offer a glimpse into the strategic maneuvers of key players. Walgreens Boots Alliance, Inc., a stalwart in the retail pharmacy sector, has consistently demonstrated robust revenue growth, peaking at approximately $147 billion in 2024. This marks a 93% increase from its 2014 revenue, showcasing its resilience and adaptability in a competitive market.

Conversely, TG Therapeutics, Inc., a biopharmaceutical company, has experienced a more volatile revenue trajectory. From a modest $152,000 in 2014, it surged to $234 million in 2023, reflecting a staggering growth rate of over 150,000%. This dramatic rise underscores TG Therapeutics' potential in the biotech arena, despite its smaller scale compared to Walgreens.

The data highlights the contrasting paths of these companies, with Walgreens' steady expansion and TG Therapeutics' explosive growth, albeit with some missing data points in 2024.